Search Result
Results for "
rearranged
" in MedChemExpress (MCE) Product Catalog:
6
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-136175
-
Revumenib
Maximum Cited Publications
15 Publications Verification
SNDX-5613
|
Epigenetic Reader Domain
|
Cancer
|
|
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
|
-
-
- HY-16993
-
OICR-9429
Maximum Cited Publications
15 Publications Verification
|
Apoptosis
WDR5
|
Cancer
|
|
OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
|
-
-
- HY-131003
-
|
DS-6051b; AB-106; IBI-344
|
ROS Kinase
|
Cancer
|
|
Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
|
-
-
- HY-15227
-
|
|
Histone Methyltransferase
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia .
|
-
-
- HY-148033
-
|
N,N,N-Trimethylchitosan
|
Drug Derivative
|
Others
|
|
Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .
|
-
-
- HY-169996
-
-
-
- HY-N6727
-
|
Aspergillin
|
Apoptosis
PKA
NF-κB
Bacterial
Fungal
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
|
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
|
-
-
- HY-162250
-
|
|
PROTACs
Histone Methyltransferase
|
Cancer
|
|
MS8847 is a PROTAC degrader and antiproliferative agent targeting EZH2 (DC50=34.4 nM in EOL-1 MLL-rAML cells). MS8847 recruits the E3 ligase von Hippel-Lindau (VHL) to mediate the degradation of EZH2 via the ubiquitin-proteasome system. MS8847 induces antiproliferative effects in MLL-rearranged acute myeloid leukemia cells and inhibits the growth of triple-negative breast cancer cell lines or 3D triple-negative breast cancer models. MS8847 is applicable to research related to MLL-rearranged acute myeloid leukemia and triple-negative breast cancer .
|
-
-
- HY-172416
-
|
ZE63-0302
|
Epigenetic Reader Domain
|
Cancer
|
|
Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia .
|
-
-
- HY-15222
-
|
|
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
|
-
-
- HY-151902
-
|
|
PROTACs
JAK
|
Cancer
|
|
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .
|
-
-
- HY-175200
-
|
|
Slit Proteins
|
Neurological Disease
Cancer
|
|
DEL-S1 is a SLIT2 binder. DEL-S1 significantly inhibits the formation of the SLIT2/ROBO1 complex by inducing conformational rearrangement, and further suppresses its function, with an IC50 of 68.8 μM. DEL-S1 can be used in studies of neurodevelopment, immunomodulation, and cancers such as glioblastoma .
|
-
-
- HY-138053
-
|
Ristomycin III
|
Antibiotic
|
Cardiovascular Disease
Infection
|
|
Ristocetin A sulfate (Ristomycin III) is a glycopeptide antibiotic that binds to von Willebrand factor (VWF) and bacterial cell wall components. Ristocetin A sulfate interferes with the biosynthesis of bacterial peptidoglycan by inhibiting transpeptidation. As an inducer of platelet adhesion and aggregation, Ristocetin A sulfate drives conformational changes by binding to the A1 domain of VWF, thereby activating downstream signaling pathways and promoting cytoskeletal rearrangement. Ristocetin A sulfate not only enhances platelet adhesion and spreading on immobilized VWF, but also induces the formation of asymmetric dimers with anticooperativity between platelets and plasma VWF. Ristocetin A sulfate is widely used in studies related to thromboembolic diseases and bacterial infections .
|
-
-
- HY-112301A
-
|
trans-BLU-667
|
RET
|
Cancer
|
|
trans-Pralsetinib (trans-BLU-667) is a rearranged during transfection (RET) inhibitor extracted from patent US20170121312A1, Compound Example 129 .
|
-
-
- HY-W008325
-
|
|
Amino Acid Derivatives
|
Others
|
|
Boc-L-Dap-OH is a Boc-protected derivative of L-2,3-diaminopropionic acid. Boc-L-Dap-OH is an important chiral amino acid derivative. Boc-L-Dap-OH can be generated via the Hofmann rearrangement of Boc-L-asparagine. Boc-L-Dap-OH serves as a starting material for the preparation of BIM analogs .
|
-
-
- HY-136360
-
MI-3454
3 Publications Verification
|
Epigenetic Reader Domain
|
Cancer
|
|
MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .
|
-
-
- HY-W042557
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Tetrabutylammonium trifluoromethanesulfonate, commonly known as TBAOTf. TBAOTf is widely used as a strong acid catalyst and phase transfer agent in organic synthesis, especially for reactions involving nucleophilic substitution, elimination, and rearrangement, in addition, it is also used as an electrolyte additive for rechargeable batteries and a stabilizer of supercritical fluids Due to its high stability, solubility and selectivity, TBAOTf is considered to be a highly efficient and multifunctional reagent in various applications.
|
-
-
- HY-156135
-
|
|
MDM-2/p53
RET
DNA/RNA Synthesis
Apoptosis
Caspase
|
Endocrinology
Cancer
|
|
NSC194598 is a p53 DNA-binding inhibitor with an IC50 value of 180 nM. NSC194598 inhibits p53 DNA binding and induction of target genesn when p53 is stabilized and activated by irradiation or chemotherapy. NSC194598 can interfere with transcriptional activation of mutated rearranged during transfection (RET) gene, induce apoptosis and G0/G1 phase arrest. NSC194598 can be used for the researches of acute radiation toxicity and medullary thyroid carcinoma .
|
-
-
- HY-149127
-
|
ASC-JM17; ALZ-003
|
Keap1-Nrf2
Androgen Receptor
HSP
Mitophagy
Ferroptosis
Apoptosis
Reactive Oxygen Species (ROS)
Autophagy
|
Metabolic Disease
|
|
Rosolutamide (ASC-JM17) is an orally active Nrf1/Nrf2 activator. Rosolutamide activates Hsf1 pathways, upregulates proteasome subunits and antioxidant enzymes, induces proteasome complex structural rearrangement, and enhances ubiquitin-proteasome system-mediated degradation. Rosolutamide reduces mutant androgen receptor and ataxin-3 aggregates, restores mitochondrial function, attenuates reactive oxygen species (ROS) levels, induces apoptosis and ferroptosis, and inhibits cancer cell growth. Rosolutamide can be used for the research of spinal and bulbar muscular atrophy, Huntington’s disease, and temozolomide-resistant glioblastoma .
|
-
-
- HY-P3245A
-
|
|
Apoptosis
|
Cancer
|
|
HXR9 hydrochloride is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 hydrochloride antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 hydrochloride selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
|
-
-
- HY-15227A
-
|
|
Histone Methyltransferase
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia .
|
-
-
- HY-151672
-
|
|
ADC Linker
|
Others
|
|
Biotin-TEG-ATFBA is a click chemistry reagent containing a perfluorophenylazide group. Biotin-TEG-ATFBA forms a highly stable azene intermediate that undergoes insertion and addition reactions (non-intermolecular rearrangement) in moderate to good yields after photolysis. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
-
- HY-Y0549
-
|
Diphenylmethane-α-carboxylic Acid
|
Biochemical Assay Reagents
|
Others
|
|
Diphenylacetic acid (Diphenylmethane-α-carboxylic Acid) is a biochemical reagent that can be used as a biological material or organic compound for life science related research. Diphenylacetic acid can be used as a reagent in the kinetic resolution of racemic 2-hydroxy-y-butyrolactones by asymmetric esterification in the presence of pivalic anhydride and chiral acyl-transfer catalyst. Diphenylacetic acid can act as a catalyst to synthesize 2-allyl-3-oxazolin-5-one derivatives via Rh-catalyzed coupling reaction of azlactones and alkynes followed by aza-Cope rearrangement .
|
-
-
- HY-170494
-
|
|
Histone Methyltransferase
|
Cancer
|
|
AS-254s is the inhibitor for absent, small, or homeotic-like 1 protein (ASH1L) with an IC50 of 94 nM (FP assay). AS-254s exhibits antiproliferative activity against MLL1-rearranged leukemic cells with GI50 <1 μM. AS-254s induces the differentiation of MLL1-r leukemic cell .
|
-
-
- HY-120937
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DC4 Crosslinker is a stable crosslinking reagent with improved activity and solubility. DC4 Crosslinker is labile cleavable with collision-induced dissociation (CID), that will be fragmented into four rearrange products containing mobilized protons .
|
-
-
- HY-114410
-
|
|
Mitochondrial Metabolism
|
Cancer
|
|
CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of MLL-r leukemia cells .
|
-
-
- HY-W585886
-
|
FK506-A
|
Drug Intermediate
|
Others
|
|
(E/Z)-FK-506 26,28-Allylic ester rearrangement impurity (FK506-A) is a Tacrolimus (HY-13756) impurity.
|
-
-
- HY-131003A
-
|
DS-6051b free base; AB-106 free base; IBI-344 free base
|
ROS Kinase
|
Cancer
|
|
Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
|
-
-
- HY-100707
-
|
|
DNA-PK
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC50 of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC50=68 µM). IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis .
|
-
-
- HY-P3245
-
|
|
Apoptosis
|
Cancer
|
|
HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
|
-
-
- HY-12843
-
|
|
CDK
ERK
|
Cancer
|
|
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .
|
-
-
- HY-W318343
-
|
2,2,2-Triphenylacetophenone; 1,2,2,2-Tetraphenylethanone
|
Biochemical Assay Reagents
|
Others
|
|
Benzopinacolone (2,2,2-Triphenylacetophenone; 1,2,2,2-Tetraphenylethanone) can be synthesized when benzopinacol reacts with acids of moderate strength, causing the pinacol rearrangement. Benzopinacolone can undergo ring-opening rearrangement via appropriate epoxides reacting with acids .
|
-
-
- HY-34595
-
|
|
RET
|
Cancer
|
|
Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity .
|
-
-
- HY-144422
-
|
|
RET
|
Cancer
|
|
RET-IN-15 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer .
|
-
-
- HY-175407
-
|
|
Drug Derivative
|
Others
|
|
18:0-20:4 PI(3,4,5)P3 (sodium) is an analogue of phosphatidylinositol. Protein-binding to PtdIns-(3,4,5)-P3 is important for cytoskeletal rearrangements and membrane trafficking. PtdIns-(3,4,5)-P3 is resistant to cleavage by PI-specific PLC .
|
-
-
- HY-W783254
-
|
PA(18:0e/0:0)
|
G Protein-coupled Receptor Kinase (GRK)
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.
|
-
-
- HY-E70714
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK can be used for the study of non-small cell lung carcinoma (NSCLC) and neuroblastoma (NB). EML4-ALK has multiple mutants. EML4 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant EML4 ALK F1174L protein that can be used to study EML4 ALK F1174L-related functions .
|
-
-
- HY-178945
-
|
|
Opioid Receptor
Interleukin Related
TNF Receptor
Sigma Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
KOR agonist 7 (Compound 29) is a highly selective κ-opioid receptor (KOR) agonist with a Ki of 138 nM. KOR agonist 7 shows no activity at μ- and δ-opioid receptors or σ1 receptor, and exhibits extremely low affinity for σ2 receptor (Ki = 2.8 μM). KOR agonist 7 significantly reduces the secretion of pro-inflammatory cytokines such as IL-6, TNF-α, and IFN-γ, while increasing the production of the anti-inflammatory cytokine IL-10. KOR agonist 7 downregulates the expression of the pro-inflammatory M1 macrophage marker CD80 and upregulates the anti-inflammatory M2 macrophage marker CD163. KOR agonist 7 holds potential for applications in analgesia and immune modulation .
|
-
-
- HY-112301AR
-
|
trans-BLU-667 (Standard)
|
RET
Reference Standards
|
Cancer
|
|
trans-Pralsetinib (Standard) is the analytical standard of trans-Pralsetinib. This product is intended for research and analytical applications. trans-Pralsetinib (trans-BLU-667) is a rearranged during transfection (RET) inhibitor extracted from patent US20170121312A1, Compound Example 129 .
|
-
-
- HY-N3458A
-
|
(-)-Isosalvipuberulin; (-)-Isopuberulin
|
Others
|
Others
|
|
Dugesin B ((-)-Isosalvipuberulin), is a rearranged clerodane diterpenoid, which can be isolated from the aerial parts of Salvia dugesii .
|
-
-
- HY-159861
-
|
|
Liposome
|
Others
|
|
Ionizable Lipid 4 is an ionizable cationic lipid and a rearrangement product of the cationic lipid CA-lipid 5 induced by hydrogen peroxide .
|
-
-
- HY-145024
-
|
|
RET
|
Cancer
|
|
RET-IN-6 is a potent RET (rearranged during transfection) inhibitor with an IC50 of 4.57 nM (CN113461670A, compound 321) .
|
-
-
- HY-N1770
-
|
3,4-Didehydrosapriparaquione
|
Others
|
Others
|
|
12-Hydroxysapriparaquinone (compound 8) is a rearranged 4,5-seco-abietane diterpenoid isolated from the petroleum ether extract of the root of Salvia rhytidea .
|
-
-
- HY-122698
-
|
|
Apoptosis
|
Cancer
|
|
CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells .
|
-
-
- HY-34595R
-
|
|
RET
|
Cancer
|
|
Pyrazoloadenine (Standard) is the analytical standard of Pyrazoloadenine. This product is intended for research and analytical applications. Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity .
|
-
-
- HY-145023
-
|
|
RET
|
Cancer
|
|
RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC50s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18) .
|
-
-
- HY-143545
-
|
|
RET
|
Cancer
|
|
RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer .
|
-
-
- HY-174993
-
|
|
RET
|
Cancer
|
|
FHND5071 (1H) is a selective inhibitor targeting the RET (rearrangement during transfection) tyrosine kinase. FHND5071 (1H) is promising for research of RET-driven cancers (such as thyroid cancer, lung cancer, etc.) .
|
-
-
- HY-124906
-
|
|
iGluR
|
Neurological Disease
|
|
JAMI1001A is a positive allosteric modulator of AMPA receptor. JAMI1001A efficaciously modulates AMPA receptor deactivation and desensitization of both flip and flop receptor isoforms .
|
-
-
- HY-114162B
-
|
SNDX-50469 mesylate
|
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.
|
-
- HY-174548
-
|
|
mRNA
|
Cancer
|
|
Human PDGFRB mRNA encodes the human platelet derived growth factor receptor beta (PDGFRB) protein, a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. PDGFRB is essential for normal development of the cardiovascular system and aids in rearrangement of the actin cytoskeleton.
|
-
- HY-160764
-
|
|
Drug Derivative
|
Others
|
|
N6-Carboxymethyl-ATP is the alkylation product of ATP with iodoacetic acid at pH 6.5, where alkylation of ATP with iodoacetic acid at pH 6.5 yielded 1-carboxymethyl-ATP which, after alkaline rearrangement gave N6-carboxymethyl-ATP .
|
-
- HY-144429
-
|
|
TRP Channel
|
Metabolic Disease
|
|
TRPC5-IN-4 is potent and safe TRPC inhibitor with IC50 value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD) .
|
-
- HY-E70713
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK is a potential molecular target in non-small cell lung carcinoma (NSCLC). EML4 ALK Recombinant Human Active Protein Kinase is a recombinant EML4 ALK protein that can be used to study EML4 ALK-related functions .
|
-
- HY-15222A
-
|
|
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 dihydrochloride downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
|
-
- HY-E70776
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET S891A is a mutant of RET. RET S891A Recombinant Human Active Protein Kinase is a recombinant RET S891A protein that can be used to study RET S891A-related functions .
|
-
- HY-N10771
-
|
|
Others
|
Others
|
|
(R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol (compound 48) is a catechol compound. (R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol involves in bioinspired synthesis of rearranged abietane diterpenes, related to pygmaeocins .
|
-
- HY-E70778
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804L is a mutant of RET. RET V804L Recombinant Human Active Protein Kinase is a recombinant RET V804L protein that can be used to study RET V804L-related functions .
|
-
- HY-E70777
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804E is a mutant of RET. RET V804E Recombinant Human Active Protein Kinase is a recombinant RET V804E protein that can be used to study RET V804E-related functions .
|
-
- HY-E70859
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L790F is a mutant of RET. RET L790F Recombinant Human Active Protein Kinase is a recombinant RET L790F protein that can be used to study RET L790F-related functions .
|
-
- HY-E70771
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L730I is a mutant of RET. RET L730I Recombinant Human Active Protein Kinase is a recombinant RET L730I protein that can be used to study RET L730I-related functions .
|
-
- HY-E70775
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R813Q is a mutant of RET. RET R813Q Recombinant Human Active Protein Kinase is a recombinant RET R813Q protein that can be used to study RET R813Q-related functions .
|
-
- HY-E70772
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L730M is a mutant of RET. RET L730M Recombinant Human Active Protein Kinase is a recombinant RET L730M protein that can be used to study RET L730M-related functions .
|
-
- HY-E70774
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R749T is a mutant of RET. RET R749T Recombinant Human Active Protein Kinase is a recombinant RET R749T protein that can be used to study RET R749T-related functions .
|
-
- HY-E70769
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810R is a mutant of RET. RET G810R Recombinant Human Active Protein Kinase is a recombinant RET G810R protein that can be used to study RET G810R-related functions .
|
-
- HY-E70766
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET E762Q is a mutant of RET. RET E762Q Recombinant Human Active Protein Kinase is a recombinant RET E762Q protein that can be used to study RET E762Q-related functions .
|
-
- HY-E70780
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y791F is a mutant of RET. RET Y791F Recombinant Human Active Protein Kinase is a recombinant RET Y791F protein that can be used to study RET Y791F-related functions .
|
-
- HY-E70781
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y806H is a mutant of RET. RET Y806H Recombinant Human Active Protein Kinase is a recombinant RET Y806H protein that can be used to study RET Y806H-related functions .
|
-
- HY-N12561
-
|
|
ERK
p38 MAPK
JNK
|
Others
|
|
Pestanoid A is a rearranged pimarane diterpenoid osteoclastogenesis inhibitor with an IC50 of 4.2 μM. Pestanoid A can be isolated from the marine mesophotic zone chalinidae sponge-associated fungus, Pestalotiopsis sp. NBUF145. Pestanoid A inhibits the receptor activator of NF-kB ligand-induced MAPK and NF-κB signaling by suppressing the phosphorylation of ERK1/2-JNK1/2-p38 MAPKs and NF-κB nuclear translocation. Pestanoid A can be used for the study of osteoporosis .
|
-
- HY-E70779
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804M is a mutant of RET. RET V804M Recombinant Human Active Protein Kinase is a recombinant RET V804M protein that can be used to study RET V804M-related functions .
|
-
- HY-E70767
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G691S is a mutant of RET. RET G691S Recombinant Human Active Protein Kinase is a recombinant RET G691S protein that can be used to study RET G691S-related functions .
|
-
- HY-E70768
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810C is a mutant of RET. RET G810C Recombinant Human Active Protein Kinase is a recombinant RET G810C protein that can be used to study RET G810C-related functions .
|
-
- HY-E70773
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET M918T is a mutant of RET. RET M918T Recombinant Human Active Protein Kinase is a recombinant RET M918T protein that can be used to study RET M918T-related functions .
|
-
- HY-E70770
-
|
|
RET
|
Cancer
|
|
Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810S is a mutant of RET. RET G810S Recombinant Human Active Protein Kinase is a recombinant RET G810S protein that can be used to study RET G810S-related functions .
|
-
- HY-E70704
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719C Recombinant Human Active Protein Kinase is a recombinant EGFR G719C protein that can be used to study EGFR G719C-related functions .
|
-
- HY-E70695
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR C797S Recombinant Human Active Protein Kinase is a recombinant EGFR C797S protein that can be used to study EGFR C797S-related functions .
|
-
- HY-E70707
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L858R Recombinant Human Active Protein Kinase is a recombinant EGFR L858R protein that can be used to study EGFR L858R-related functions .
|
-
- HY-E70708
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L861Q Recombinant Human Active Protein Kinase is a recombinant EGFR L861Q protein that can be used to study EGFR L861Q-related functions .
|
-
- HY-E70705
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719S Recombinant Human Active Protein Kinase is a recombinant EGFR G719S protein that can be used to study EGFR G719S-related functions .
|
-
- HY-E70706
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L718Q Recombinant Human Active Protein Kinase is a recombinant EGFR L718Q protein that can be used to study EGFR L718Q-related functions .
|
-
- HY-E70709
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M Recombinant Human Active Protein Kinase is a recombinant EEGFR T790M protein that can be used to study EGFR T790M-related functions .
|
-
- HY-E70697
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750 Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750 protein that can be used to study EGFR d746-750-related functions .
|
-
- HY-E70703
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d752-759 Recombinant Human Active Protein Kinase is a recombinant EGFR d752-759 protein that can be used to study EGFR d752-759-related functions .
|
-
- HY-W339833
-
|
|
Biochemical Assay Reagents
|
|
|
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.
|
-
- HY-E70711
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR T790M/L858R protein that can be used to study EGFR T790M/L858R-related functions .
|
-
- HY-164482
-
|
|
RET
|
Cancer
|
|
HG-6-63-01 is a type II RET tyrosine kinase inhibitor (TKI). HG-6-63-01 also inhibits REarranged during Transfection (RET) kinase and signaling in human thyroid cancer cell lines carrying oncogenic RET alleles. HG-6-63-01 impairs phosphorylation and signalling of RET oncogenic mutants. HG-6-63-01 blunts proliferation of RET/C634R and RET/M918T-transformed fibroblasts and of RET mutant thyroid cancer cells, which is promising for research of cancers harboring oncogenic activation of RET .
|
-
- HY-E70701
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d747-749/A750P Recombinant Human Active Protein Kinase is a recombinant EGFR d747-749/A750P protein that can be used to study EGFR d747-749/A750P-related functions .
|
-
- HY-W711011
-
|
|
Drug Derivative
|
Metabolic Disease
|
|
Flufenamic acid glucuronide is an acyl-linked glucuronide of Flufenamic acid (HY-B1221). Flufenamic acid glucuronide can be used for the research of acyl glucuronide rearrangement and drug metabolism .
|
-
- HY-N15172
-
|
|
Others
|
Others
|
|
Diadinochrome, a carotenoid, is a rearrangement product of diadinoxanthin that is produced by acidic catalysis during extraction .
|
-
- HY-P2872A
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Thioglucosidase, Sinapis alba (white mustard) seed (EC 3.2.1.147) hydrolyzes the S-glucosidic bond of a glucosinolate substrate to form an unstable aglycone that rearranges with the loss of sulfate primarily to the isothiocyanate, though thiocyanates and nitriles are also formed.
|
-
- HY-181790
-
|
|
Ligands for Target Protein for PROTAC
Histone Methyltransferase
|
Cancer
|
|
DOT1L ligand-2 (Compound 52) is a DOT1L ligand. DOT1L ligand-2 acts as a Ligand for Target Protein for PROTAC, which is used to develop and design degraders of PROTAC DOT1L, such as DOT1L808 (HY-181789). DOT1L ligand-2 is applicable to research related to MLL-rearranged leukemia .
|
-
- HY-136175B
-
|
cis-SNDX-5613
|
Epigenetic Reader Domain
|
Cancer
|
|
cis-Revumenib (cis-SNDX-5613) is an isomer of Revumenib (HY-136175). Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
|
-
- HY-181787
-
|
|
PROTACs
Histone Methyltransferase
|
Cardiovascular Disease
|
|
DOT1L705 is a PROTAC degrader that targets DOT1L. DOT1L705 recruits the VHL E3 ubiquitin ligase to induce proteasomal degradation of DOT1L. DOT1L705 reduces the viability of leukemia cells. DOT1L705 inhibits H3K79 methylation. DOT1L705 can be used in studies related to MLL-rearranged leukemia .
|
-
- HY-181834
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
PROTAC MLLT1 Degrader-1 is a PROTAC degrader targeting MLLT1. PROTAC MLLT1 Degrader-1 inhibits AML cell proliferation and viability, suppresses tumor growth in human AML xenograft models, and can block the oncogene transcriptional program. PROTAC MLLT1 Degrader-1 can be used for the research of MLL-rearranged acute myeloid leukemia (AML) .
|
-
- HY-183050
-
|
|
Mas-related G-protein-coupled Receptor (MRGPR)
|
Others
|
|
HEP-50768 is an orally active and selective MRGPRX4 (hX4) antagonist. HEP-50768 suppresses basal and bile-acid-stimulated hX4 activity. HEP-50768 binds the receptor’s transmembrane pocket and induces extracellular loop rearrangements. HEP-50768 modulates GPCR microswitch motifs and reduces bile-acid-induced pruritic scratching behaviors. HEP-50768 can be used for the research of cholestatic pruritus .
|
-
- HY-182346
-
|
|
FBPase
|
Metabolic Disease
|
|
FBPase-IN-7 is a fructose-1,6-bisphosphatase (FBPase) inhibitor with an IC50 of 0.75 μM. FBPase-IN-7 binds to a cryptic allosteric pocket of FBPase, induces conformational rearrangement of key residues, forms a hydrogen-bond network, and disrupts substrate catalysis. FBPase-IN-7 confirms cellular stabilizes HuFBPase in hepatic cells. FBPase-IN-7 has hypoglycemic activity. FBPase-IN-7 can be used for the research of type 2 diabetes .
|
-
- HY-115619
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
EPZ004777 formate is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 formate reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 formate selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 formate can be used for the study of leukemia .
|
-
- HY-181690
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML) .
|
-
- HY-P992174
-
|
|
RSV
|
Infection
|
|
ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
|
-
- HY-W713877
-
|
Montelukast AG
|
Drug Metabolite
|
Others
|
|
Montelukast acyl-b-D-glucuronide (Montelukast AG) is a acyl glucuronide metabolite of Montelukast (HY-13315A) .
|
-
- HY-E70696
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR C797S/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR C797S/L858R protein that can be used to study EGFR C797S/L858R-related functions .
|
-
- HY-E70698
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/C797S protein that can be used to study EGFR d746-750/C797S-related functions .
|
-
- HY-E70702
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d747-752/P753S Recombinant Human Active Protein Kinase is a recombinant EGFR d747-752/P753S protein that can be used to study EGFR d747-752/P753S-related functions .
|
-
- HY-116116
-
|
SIM010603
|
c-Kit
RET
VEGFR
|
Cancer
|
|
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
|
-
- HY-162350
-
|
|
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
TDI-11055 is a selective and orally active eleven-nineteen leukemia (ENL) inhibitor, which displaces ENL from chromatin by blocking its YEATS domain interaction with acylated histones. TDI-11055 inhibits ENL and AF9 YEATS domains with IC50 values of 50 nM and 70 nM, respectively, and no activity against GAS41 or YEATS2. TDI-11055 decreases chromatin occupancy of ENL-associated complexes, impairs transcription elongation, suppresses key oncogenic gene expression programs, and induces differentiation. TDI-11055 can be used for the research of acute myeloid leukemia .
|
-
- HY-151292
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Antitumor agent-74 (compound 13da) is a quinoxalines derivative, an antitumor agent. Antitumor agent-74 exhibits more potent efficacy on tumor inhibition, mixed with regioisomer Antitumor agent-75(HY-151295, compound 14 da) (mriBIQ 13da/14da). mriBIQ 13da/14da attests cell cycle at S phase, inhibits DNA synthesis, and induces mithochondrial apoptosis .
|
-
- HY-156794
-
|
DSP-5336
|
Epigenetic Reader Domain
FLT3
|
Cancer
|
Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .
|
-
- HY-183729
-
|
|
Ligands for Target Protein for PROTAC
RET
|
Endocrinology
Cancer
|
|
RET-IN-34 (Compound EV1) is a RET inhibitor with an IC50 of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma .
|
-
- HY-156794A
-
|
DSP-5336 enantiomer
|
Drug Isomer
FLT3
Epigenetic Reader Domain
|
Cardiovascular Disease
Cancer
|
Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib (HY-156794). Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .
|
-
- HY-182913
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-122 is a SARS-CoV-2 inhibitor by targeting the S2 subunit of the spike protein. SARS-CoV-2-IN-122 interacts with residues linked to membrane fusion-associated conformational rearrangements, interfering with viral entry events. SARS-CoV-2-IN-122 inhibits SARS-CoV-2 replication, lacks direct virucidal activity, and does not impair viral-host cell attachment. SARS-CoV-2-IN-122 exhibits activity against SARS-CoV-2 variants including B.1 and Omicron (BA.2.86.1). SARS-CoV-2-IN-122 can be used for the research of coronavirus disease 2019 (COVID-19) .
|
-
- HY-E70699
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S protein that can be used to study EGFR d746-750/T790M/C797S-related functions .
|
-
- HY-159805
-
|
|
CDK
|
Cancer
|
|
CDK2-IN-31 is a CCNE1:CDK2 complex inhibitor with an IC50 of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer .
|
-
- HY-E70700
-
|
|
EGFR
|
Cancer
|
|
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S/L858R protein that can be used to study EGFR d746-750/T790M/C797S/L858R-related functions .
|
-
- HY-D3157
-
|
|
Fluorescent Dye
|
Others
|
|
Photoactive esterase probe is a photoactivatable fluorescent probe for esterase. Photoactive esterase probe is used for the detection and imaging of esterase activity in living cells .
|
-
- HY-178061
-
|
|
ERK
RET
|
Cancer
|
|
APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
|
-
- HY-NP008
-
|
|
Lipocalin Family
|
Inflammation/Immunology
|
|
β-Lactoglobulin, a major whey protein, is a small globular protein from the lipocalin family. β-Lactoglobulin is an important source of the essential and branched-chain amino acids (leucine, isoleucine, and valine). β-Lactoglobulin shows antioxidant properties, because it contains two disulfide bonds and one free thiol group. β-Lactoglobulin is a ligand transport agent. β-Lactoglobulin is one of the major allergens in milk and can be utilized in the research for developing safe hypoallergenic dairy products .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D3157
-
|
|
Fluorescent Dyes
|
|
Photoactive esterase probe is a photoactivatable fluorescent probe for esterase. Photoactive esterase probe is used for the detection and imaging of esterase activity in living cells .
|
| Cat. No. |
Product Name |
Type |
-
- HY-148033
-
|
N,N,N-Trimethylchitosan
|
Biochemical Assay Reagents
|
|
Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .
|
-
- HY-NP008
-
|
|
Biochemical Assay Reagents
|
|
β-Lactoglobulin, a major whey protein, is a small globular protein from the lipocalin family. β-Lactoglobulin is an important source of the essential and branched-chain amino acids (leucine, isoleucine, and valine). β-Lactoglobulin shows antioxidant properties, because it contains two disulfide bonds and one free thiol group. β-Lactoglobulin is a ligand transport agent. β-Lactoglobulin is one of the major allergens in milk and can be utilized in the research for developing safe hypoallergenic dairy products .
|
-
- HY-W008325
-
|
|
Biochemical Assay Reagents
|
|
Boc-L-Dap-OH is a Boc-protected derivative of L-2,3-diaminopropionic acid. Boc-L-Dap-OH is an important chiral amino acid derivative. Boc-L-Dap-OH can be generated via the Hofmann rearrangement of Boc-L-asparagine. Boc-L-Dap-OH serves as a starting material for the preparation of BIM analogs .
|
-
- HY-W042557
-
|
|
Biochemical Assay Reagents
|
|
Tetrabutylammonium trifluoromethanesulfonate, commonly known as TBAOTf. TBAOTf is widely used as a strong acid catalyst and phase transfer agent in organic synthesis, especially for reactions involving nucleophilic substitution, elimination, and rearrangement, in addition, it is also used as an electrolyte additive for rechargeable batteries and a stabilizer of supercritical fluids Due to its high stability, solubility and selectivity, TBAOTf is considered to be a highly efficient and multifunctional reagent in various applications.
|
-
- HY-Y0549
-
|
Diphenylmethane-α-carboxylic Acid
|
Biochemical Assay Reagents
|
|
Diphenylacetic acid (Diphenylmethane-α-carboxylic Acid) is a biochemical reagent that can be used as a biological material or organic compound for life science related research. Diphenylacetic acid can be used as a reagent in the kinetic resolution of racemic 2-hydroxy-y-butyrolactones by asymmetric esterification in the presence of pivalic anhydride and chiral acyl-transfer catalyst. Diphenylacetic acid can act as a catalyst to synthesize 2-allyl-3-oxazolin-5-one derivatives via Rh-catalyzed coupling reaction of azlactones and alkynes followed by aza-Cope rearrangement .
|
-
- HY-W339833
-
|
|
Biochemical Assay Reagents
|
|
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3245A
-
|
|
Apoptosis
|
Cancer
|
|
HXR9 hydrochloride is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 hydrochloride antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 hydrochloride selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
|
-
- HY-P3245
-
|
|
Apoptosis
|
Cancer
|
|
HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells .
|
-
- HY-P5423C
-
|
|
Peptides
|
Others
|
|
GALA-Cys is a chemically modified GALA peptide (HY-P5423) that retains GALA functions while acquiring strong covalent conjugation capability. GALA-Cys undergoes pH-driven reversible secondary structure transition, rearranges into an amphipathic α-helix, self-oligomerizes, penetrates lipid membranes to form pores, and disrupts lipid bilayers, thereby enabling endosomal escape and cytosolic cargo delivery. GALA-Cys can be conjugated with lipid DPTE for integration into liposomes, self-assembles into a tilted monolayer on gold surfaces, and serves as a pH-responsive coating for particle surface functionalization. GALA-Cys is applicable to studies related to targeted cargo delivery .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P992174
-
|
|
RSV
|
Infection
|
|
ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N6727
-
-
-
- HY-N3458A
-
-
-
- HY-N10771
-
|
|
Flavonoids
Terpenoids
Gramineae
Morus nigra Linn.
Diterpenoids
Plants
Moraceae
Other Flavonoids
Saccharum officinarum
Source Classification
|
Others
|
|
(R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol (compound 48) is a catechol compound. (R)-2-Isopropyl-8,8,8a-trimethyl-6,7,8,8a-tetrahydrophenanthrene-3,4-diol involves in bioinspired synthesis of rearranged abietane diterpenes, related to pygmaeocins .
|
-
-
- HY-N12561
-
|
|
Microorganisms
Terpenoids
Diterpenoids
Source Classification
|
ERK
p38 MAPK
JNK
|
|
Pestanoid A is a rearranged pimarane diterpenoid osteoclastogenesis inhibitor with an IC50 of 4.2 μM. Pestanoid A can be isolated from the marine mesophotic zone chalinidae sponge-associated fungus, Pestalotiopsis sp. NBUF145. Pestanoid A inhibits the receptor activator of NF-kB ligand-induced MAPK and NF-κB signaling by suppressing the phosphorylation of ERK1/2-JNK1/2-p38 MAPKs and NF-κB nuclear translocation. Pestanoid A can be used for the study of osteoporosis .
|
-
-
- HY-N15172
-
-
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-151672
-
|
|
|
Azide
|
|
Biotin-TEG-ATFBA is a click chemistry reagent containing a perfluorophenylazide group. Biotin-TEG-ATFBA forms a highly stable azene intermediate that undergoes insertion and addition reactions (non-intermolecular rearrangement) in moderate to good yields after photolysis. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-148033
-
|
N,N,N-Trimethylchitosan
|
|
Polymers
|
|
Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .
|
-
- HY-W783254
-
|
PA(18:0e/0:0)
|
|
Phospholipids
|
|
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.
|
-
- HY-159861
-
|
|
|
Cationic Lipids
|
|
Ionizable Lipid 4 is an ionizable cationic lipid and a rearrangement product of the cationic lipid CA-lipid 5 induced by hydrogen peroxide .
|
-
- HY-174548
-
|
|
|
mRNA
|
|
Human PDGFRB mRNA encodes the human platelet derived growth factor receptor beta (PDGFRB) protein, a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. PDGFRB is essential for normal development of the cardiovascular system and aids in rearrangement of the actin cytoskeleton.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
